NCT06853678View on ClinicalTrials.gov

Second-line Immunotherapy for ES-SCLC

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

March 1, 2027

Conditions
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
DRUG

Adebrelimab

1200mg,d1,iv,q3w

DRUG

Selinexor

40mg,twice weekly,d1, d3,oral,q3w

DRUG

Nab-paclitaxel

100mg/m2,d1,d8,d15,iv,q3w

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER